{"gene":"GALR2","run_date":"2026-04-28T18:06:52","timeline":{"discoveries":[{"year":1998,"finding":"GalR2 couples to Gq/G11 to stimulate phospholipase C and inositol phosphate production (7-fold increase), and also couples modestly to Gi (30% inhibition of forskolin-stimulated cAMP) and Go-mediated MAPK activation in CHO cells; GalR2-mediated MAPK activation is PKC-dependent and not sensitive to beta-ARKct (Gbetagamma inhibitor), distinguishing it mechanistically from GalR1.","method":"Stable CHO cell expression, cAMP assay, inositol phosphate accumulation, MAPK activity assay, pertussis toxin treatment, PKC inhibitor, beta-ARKct expression","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal signaling assays in stably transfected cells with pharmacological dissection of G protein coupling","pmids":["9578554"],"is_preprint":false},{"year":1998,"finding":"Human GALR2 couples to Galphaq/11 to stimulate phospholipase C and increase intracellular calcium, and also to Galphai/o to inhibit adenylate cyclase; high-affinity galanin binding (Kd ~0.3 nM) requires intact N-terminal but not C-terminal galanin fragments.","method":"Stable HEK-293 expression, [125I]galanin radioligand binding, cAMP assay, calcium/aequorin luminescence, Xenopus melanophore assay","journal":"Brain research. Molecular brain research","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal functional assays confirmed in human receptor expressed in two heterologous systems","pmids":["9685625"],"is_preprint":false},{"year":1998,"finding":"Human GALR2 couples to phospholipase C/calcium mobilization, distinguishing it from GALR1 and GALR3 which signal predominantly through inhibition of adenylate cyclase; galanin binds with Kd ~0.3 nM.","method":"Radioligand binding ([125I]galanin), aequorin luminescence calcium assay, Xenopus melanophore assay in HEK-293 cells","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1-2 — orthogonal pharmacological characterization of human receptor replicated across multiple cell systems","pmids":["9832121"],"is_preprint":false},{"year":1998,"finding":"Mouse GalR2 signals through phosphoinositide metabolism (Gq-coupled) in a pertussis toxin-insensitive manner, confirming Gq (not Gi/Go) as the primary coupling partner; high-affinity galanin binding (Kd = 0.47 nM) requires N-terminal but not C-terminal galanin sequences.","method":"COS-7 cell transfection, [125I]galanin radioligand binding, phosphoinositide metabolism assay, pertussis toxin treatment","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro reconstitution with pharmacological dissection, replicated across species","pmids":["9832122"],"is_preprint":false},{"year":1999,"finding":"Membrane cholesterol is required for galanin binding to GalR2; depletion by methyl-beta-cyclodextrin or lipoprotein-deficient serum markedly reduces binding, which is restored by cholesterol repletion. GalR2 binds multiple cholesterol molecules cooperatively (Hill n ≥ 3). Cholesterol also modulates downstream Gq/inositol phosphate signaling, independently of G protein interaction.","method":"Cholesterol depletion/repletion in CHO/GalR2 cells, radioligand binding, Hill analysis, filipin clustering, cholesterol oxidase treatment, inositol phosphate assay, GTPgammaS preincubation","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal perturbations with rigorous controls establishing cholesterol as a mechanistic regulator of GalR2 ligand binding and signaling","pmids":["10508403"],"is_preprint":false},{"year":1998,"finding":"GalR2 is the receptor subtype mediating galanin-induced jejunal contraction; pharmacological profile of GalR-selective ligands in jejunal contraction matched only GalR2, and only GalR2 mRNA was detected in the tissue.","method":"GalR-selective ligand pharmacology in rat jejunal contraction assay, Northern blot/RT-PCR for receptor mRNA","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological matching with receptor expression, single lab","pmids":["9742938"],"is_preprint":false},{"year":1998,"finding":"GalR2 mRNA is markedly upregulated (~3.7-fold at day 7) in facial motor neurons after unilateral facial nerve crush, while GalR1 mRNA is absent in facial nuclei; this inducible GalR2 upregulation suggests an autoreceptor role in nerve injury response.","method":"In situ hybridization histochemistry quantification after facial nerve crush in rats","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — direct quantitative measurement of receptor mRNA with injury model, single lab","pmids":["9681481"],"is_preprint":false},{"year":2001,"finding":"GalR2 receptor activation mediates pronociceptive (allodynic) effects of low-dose galanin in the spinal cord; intrathecal infusion of the GalR2-specific agonist AR-M1896 induces mechanical and cold allodynia in normal rats, whereas antiallodynic effects of high-dose galanin in neuropathic pain are mediated by GalR1.","method":"Intrathecal infusion of GalR2-selective agonist AR-M1896 and GalR1/2 agonist AR-M961 in rat Bennett neuropathic pain model, mechanical and cold allodynia testing","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — selective agonist pharmacology with defined behavioral readout, replicated across receptor subtypes in vivo","pmids":["11481429"],"is_preprint":false},{"year":2003,"finding":"GalR2 activation mediates galanin-induced neurite outgrowth from adult dorsal root ganglion sensory neurons via a PKC-dependent signaling pathway; GalR2-specific agonist has equipotent effects to galanin on neurite extension, PKC inhibition reduces outgrowth to galanin-knockout levels, and GalR1 knockout/antagonism has no effect.","method":"GalR1 knockout animals, GalR1-specific antagonist, GalR2-specific agonist, PKC inhibitor, DRG neurite outgrowth assay, galanin knockout cultures","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout plus selective pharmacological tools with quantitative cellular readout, multiple converging lines of evidence","pmids":["12533601"],"is_preprint":false},{"year":2003,"finding":"GalR2 activation in SH-SY5Y neuroblastoma cells induces apoptosis via caspase-3 activation, PARP cleavage, and DNA laddering; this effect is far more potent (100-fold lower EC50) and pronounced than GalR1 activation in the same cell type.","method":"Tetracycline-inducible GalR1/GalR2 expression in SH-SY5Y cells, cell viability, caspase-3 activation, PARP cleavage, DNA laddering, microphysiometry","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — inducible receptor expression system with multiple apoptosis markers, direct receptor-subtype comparison","pmids":["14592962"],"is_preprint":false},{"year":2007,"finding":"GalR2 mediates neuroprotection in hippocampal neurons by activating Akt and ERK phosphorylation; galanin-induced Akt phosphorylation is abolished in GalR2 loss-of-function mutant animals. Inhibitors of ERK or Akt confirm that GalR2-dependent activation of these kinases contributes to protection against glutamate-induced cell death.","method":"GalR2 loss-of-function mutant mice, hippocampal cultures, galanin/glutamate treatment, Western blot for pAkt and pERK, specific kinase inhibitors","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function plus pharmacological inhibitors with quantitative signaling readouts","pmids":["17263796"],"is_preprint":false},{"year":2007,"finding":"GalR2 is expressed presynaptically in substantia gelatinosa neurons, where its activation by selective agonist AR-M1896 consistently decreases membrane excitability and increases the interevent interval of spontaneous EPSCs; GalR1 cocktail does not affect EPSCs, demonstrating distinct pre- versus postsynaptic localization.","method":"Whole-cell patch-clamp recording from rat substantia gelatinosa neurons, GalR2-selective agonist AR-M1896, GalR2 antagonist M871, current-voltage analysis, EPSC recording","journal":"Pain","confidence":"High","confidence_rationale":"Tier 1-2 — electrophysiology with selective agonist/antagonist tools establishing pre- and postsynaptic actions","pmids":["17910903"],"is_preprint":false},{"year":2008,"finding":"GalR2 activation in PC12 cells stably expressing GFP-tagged GalR2 induces caspase-dependent apoptosis via Gq/11-type signaling, associated with downregulation of pAkt and pBad; PI3K inhibition increases pBad and decreases caspase activation, confirming PI3K/Akt pathway involvement downstream of GalR2.","method":"Stable GFP-GalR2 transfection in PC12 cells, Western blot for pAkt/pBad, caspase activation assay, PI3K inhibitor LY-294002, FACS cell cycle analysis, real-time PCR","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal assays with pharmacological dissection of downstream pathway","pmids":["18272487"],"is_preprint":false},{"year":2010,"finding":"CYM2503, a positive allosteric modulator of GalR2, potentiates galanin-stimulated IP1 accumulation in HEK293/GalR2 cells without displacing [125I]galanin from the orthosteric binding site, demonstrating allosteric modulation of GalR2 Gq signaling; this compound shows anticonvulsant efficacy in rodent seizure models.","method":"IP1 accumulation assay in HEK293/GalR2 cells, [125I]galanin radioligand binding competition, rat Li-pilocarpine seizure model, mouse electroshock model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — mechanistic binding and signaling assays confirming allosteric mechanism, validated in vivo","pmids":["20660766"],"is_preprint":false},{"year":2014,"finding":"GalR1 and GalR2 form heteroreceptor complexes detectable by proximity ligation assay (PLA) and BRET2 in HEK293T cells and in the raphe-hippocampal system; within these complexes, galanin(1-15) preferentially activates the GalR1 protomer (inhibiting CREB/cAMP via Gi) while galanin(1-29) shows higher efficacy at the GalR2 protomer (activating Gq/NFAT signaling), revealing allosteric receptor-receptor interactions.","method":"Proximity ligation assay, BRET2 assay in HEK293T cells, CRE luciferase reporter, NFAT luciferase reporter, GalR2 antagonist M871, galanin antagonist M35","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal assays (BRET2, PLA, functional reporters) establishing heteroreceptor complex formation and biased signaling","pmids":["25152404"],"is_preprint":false},{"year":2014,"finding":"GALR2 promotes tumor angiogenesis in head and neck squamous cell carcinoma via p38-MAPK-mediated activation of RAP1B, which phosphorylates/inactivates tristetraprolin (TTP), stabilizing VEGF and IL-6 mRNA transcripts and enhancing their secretion; p38 inhibition reactivates TTP and decreases cytokine secretion.","method":"ELISA for cytokines, in vitro angiogenesis assay, p38 chemical inhibitor, genetic knockdown of RAP1B and TTP, mouse xenograft, chick chorioallantoic membrane, orthotopic floor-of-mouth model","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 2 — chemical and genetic knockdown strategies with in vitro and in vivo validation, mechanistic pathway dissection","pmids":["24568968"],"is_preprint":false},{"year":2021,"finding":"GALR2 activation by baicalin upregulates GLUT4 expression and glucose uptake through p38MAPK and AKT pathways and the PGC-1alpha-GLUT4 axis in skeletal muscle; GALR2 antagonist M871 and GALR2 siRNA knockdown abolish these effects, demonstrating that GALR2 is the required mediator.","method":"Obese mouse model with GALR2 antagonist M871, GALR2 knockdown L6 myotubes, Western blot for PGC-1alpha/GLUT4/p-p38/p-AKT/p-AS160, glucose consumption assay","journal":"Phytomedicine","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockdown plus pharmacological antagonism with defined signaling readouts, single lab","pmids":["34923235"],"is_preprint":false},{"year":2022,"finding":"GalR2 is the dominant galanin receptor subtype in mouse cardiomyocytes and hearts; genetic suppression of GalR2 promotes cardiac hypertrophy, fibrosis, and mitochondrial oxidative stress in vivo, while GalR2 siRNA in vitro abolishes galanin's protective effects against cell hypertrophy and mitochondrial ROS production.","method":"GalR2 genetic suppression in mice, siRNA knockdown in H9C2 cardiomyoblasts, cardiac histology, mitochondrial ROS measurement","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo and in vitro loss-of-function with defined cardiac phenotypes, single lab","pmids":["35431947"],"is_preprint":false},{"year":2022,"finding":"Nerve-derived galanin activates GALR2 in salivary adenoid cystic carcinoma cells, inducing epithelial-to-mesenchymal transition (EMT) and promoting perineural invasion; GALR2 antagonist M871 blocks these effects both in vitro and in vivo.","method":"Transcriptome sequencing, Western blot for EMT markers, Transwell invasion assay, in vitro and in vivo perineural invasion models, GALR2 antagonist M871","journal":"Cancer medicine","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological inhibition with in vitro and in vivo models, mechanistic pathway identification","pmids":["36039037"],"is_preprint":false},{"year":2023,"finding":"GalR2 is the principal receptor subtype transducing cardioprotective effects of galanin in myocardial ischemia/reperfusion injury; the GalR2-selective agonist peptide G1 (1 mg/kg i.v.) reduced infarct size by 35% and CK-MB activity by 43%, and these effects were abolished by the selective GalR2 antagonist M871.","method":"LAD coronary artery occlusion/reperfusion in rats, GalR2-selective agonist and antagonist (M871), infarct size measurement, plasma CK-MB activity","journal":"Fundamental & clinical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — selective pharmacological tools with defined cardiac readouts in vivo, antagonist rescue confirms receptor specificity","pmids":["37249014"],"is_preprint":false},{"year":2025,"finding":"GALR2 mediates the anti-inflammatory effects of a naturally occurring long galanin isoform (cGAL53) via beta-arrestin2-biased signaling rather than canonical Gq; these effects were abolished in Galr2-deficient mice and in epithelial cell-specific Arrb2 knockout mice, demonstrating that GALR2/beta-arrestin2 pathway protects the gut barrier and reduces colitis-associated inflammation.","method":"Galr2 knockout mice, epithelial cell-specific Arrb2 and Gnaq conditional knockouts, DSS-induced colitis model, colon histology, inflammatory markers","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — multiple conditional knockout models orthogonally dissecting canonical vs. biased GALR2 signaling with in vivo disease model validation","pmids":["41390752"],"is_preprint":false},{"year":2007,"finding":"GAL-R2, expressed in rat adrenocortical cells, couples to the adenylate cyclase/PKA signaling cascade to stimulate corticosterone secretion; immunoblockade of GAL-R2 (and GAL-R1) reduced galanin binding and abolished cAMP and corticosterone responses, while PLC inhibitor and PKC inhibitor had no effect.","method":"Dispersed rat adrenocortical cells, immunoblockade of receptor subtypes, [3H]galanin binding, cAMP and inositol phosphate assays, adenylate cyclase inhibitor SQ-22536, PKA inhibitor H-89, PKC inhibitor","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological dissection with multiple inhibitors in primary cells, context-specific cAMP coupling distinct from CHO cell data","pmids":["17143559"],"is_preprint":false},{"year":2011,"finding":"GalR2/3 activation by Gal2-11 promotes proliferation and trophic survival of postnatal hippocampal subgranular zone precursors and neuroblasts; no effect was observed via GalR1, demonstrating receptor-subtype specificity for hippocampal neurogenesis.","method":"Postnatal hippocampal precursor culture, GalR2/3 agonist Gal2-11, proliferation and survival assays","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — subtype-selective agonist with defined cellular readout, single lab","pmids":["21281311"],"is_preprint":false},{"year":2019,"finding":"GalR2 mediates galanin's protective effects against oxidative stress in rat cortical astrocytes; GalR2 agonist AR-M1896 mimics galanin protection against H2O2 toxicity and suppresses H2O2-induced upregulation of pERK1/2, with GalR2 showing higher expression than GalR1 or GalR3 in these cells.","method":"Primary rat cortical astrocyte culture, H2O2 oxidative stress, GalR2-selective agonist AR-M1896, Western blot for pERK1/2, cell viability assay","journal":"Mediators of inflammation","confidence":"Medium","confidence_rationale":"Tier 2 — selective agonist with signaling pathway readout in primary cells, single lab","pmids":["31249471"],"is_preprint":false}],"current_model":"GALR2 is a Gq/G11-coupled (and modestly Gi/Go-coupled) GPCR that, upon galanin binding, activates phospholipase C/PKC signaling to drive inositol phosphate production, calcium mobilization, and PKC-dependent MAPK activation; downstream of these pathways GALR2 promotes neurite outgrowth, hippocampal neuroprotection (via Akt and ERK), sensory neuron sensitization (pronociception at low doses), neuroblastoma/PC12 cell apoptosis (via caspase-3 and Akt/Bad), tumor angiogenesis (via RAP1B/p38/TTP/VEGF-IL-6), and gut epithelial protection (via beta-arrestin2-biased signaling); membrane cholesterol is required for ligand binding and downstream signaling, and GALR2 can form heteroreceptor complexes with GalR1 (and NPY1R) that allosterically reshape its pharmacology."},"narrative":{"teleology":[{"year":1998,"claim":"Establishing the primary signaling identity of GALR2: multiple groups independently demonstrated that GALR2 couples predominantly to Gq/G11 to activate PLC and inositol phosphate/calcium signaling, with modest Gi/Go-mediated cAMP inhibition and PKC-dependent MAPK activation, distinguishing it mechanistically from GalR1 and GalR3.","evidence":"Heterologous expression in CHO, HEK-293, COS-7, and Xenopus melanophore systems with cAMP, inositol phosphate, calcium, and MAPK assays plus pertussis toxin and PKC inhibitor dissection","pmids":["9578554","9685625","9832121","9832122"],"confidence":"High","gaps":["Endogenous G-protein stoichiometry may differ from overexpression systems","Structural basis for preferential Gq over Gi coupling unknown"]},{"year":1998,"claim":"Identifying GALR2 as the functional galanin receptor subtype in smooth muscle contraction resolved which receptor mediates galanin's gut motility effects, linking GALR2 Gq signaling to a defined physiological output.","evidence":"Pharmacological profiling with GalR-selective ligands in rat jejunal contraction assay combined with Northern blot/RT-PCR","pmids":["9742938"],"confidence":"Medium","gaps":["Genetic confirmation with GALR2 knockout in gut tissue not performed","Downstream contractile signaling pathway not dissected"]},{"year":1999,"claim":"Demonstrating that membrane cholesterol is an obligate modulator of GALR2 ligand binding and downstream Gq signaling revealed a lipid-dependent regulatory layer operating independently of G-protein coupling.","evidence":"Cholesterol depletion/repletion in CHO/GalR2 cells with radioligand binding, Hill analysis, and inositol phosphate assays","pmids":["10508403"],"confidence":"High","gaps":["Direct cholesterol binding site on GALR2 not identified","No structural data for cholesterol-receptor interaction"]},{"year":2001,"claim":"Establishing GALR2 as a pronociceptive receptor in the spinal cord — where low-dose galanin induces allodynia via GALR2 while high-dose antiallodynia is GalR1-mediated — resolved a long-standing paradox of galanin's bidirectional effects on pain.","evidence":"Intrathecal infusion of GalR2-selective agonist AR-M1896 in rat neuropathic pain model with mechanical and cold allodynia testing","pmids":["11481429"],"confidence":"High","gaps":["Downstream intracellular pathway linking GALR2 activation to allodynia not identified","GALR2 knockout confirmation not performed"]},{"year":2003,"claim":"Two independent studies established GALR2 as an effector of both neurite outgrowth (via PKC) in sensory neurons and caspase-3-dependent apoptosis in neuroblastoma cells, revealing divergent cell-type-dependent outcomes of the same Gq/PKC pathway.","evidence":"GalR1 knockout mice plus selective agonist/antagonist pharmacology in DRG neurite outgrowth assay; inducible GalR2 expression in SH-SY5Y with caspase-3, PARP cleavage, and DNA laddering assays","pmids":["12533601","14592962"],"confidence":"High","gaps":["Branching point determining growth versus death outcome not identified","Role of Gi coupling in apoptosis not excluded"]},{"year":2007,"claim":"Genetic loss-of-function in mice demonstrated that GALR2 is required for galanin-induced Akt and ERK phosphorylation in hippocampal neurons and for protection against glutamate excitotoxicity, establishing GALR2 as a neuroprotective receptor.","evidence":"GalR2 loss-of-function mutant mice, hippocampal cultures, Western blot for pAkt/pERK, kinase inhibitors","pmids":["17263796"],"confidence":"High","gaps":["Nature of the GalR2 loss-of-function allele limits generalizability","Relative contribution of Akt versus ERK arm not fully resolved"]},{"year":2007,"claim":"Electrophysiological recordings established that GALR2 acts presynaptically in spinal substantia gelatinosa neurons to decrease excitability and modulate excitatory synaptic transmission, providing a synaptic-level mechanism for galanin's sensory modulatory effects.","evidence":"Whole-cell patch-clamp with GalR2-selective agonist AR-M1896 and antagonist M871 in rat substantia gelatinosa neurons","pmids":["17910903"],"confidence":"High","gaps":["Ion channel target downstream of presynaptic GALR2 not identified","Post-synaptic GalR2 contributions not fully dissected"]},{"year":2008,"claim":"Mechanistic dissection in PC12 cells revealed that GALR2-induced apoptosis proceeds via Gq-coupled downregulation of pAkt and pBad, placing Bad dephosphorylation as the specific pro-apoptotic switch downstream of GALR2.","evidence":"Stable GFP-GalR2 PC12 cells, Western blot for pAkt/pBad, caspase assay, PI3K inhibitor LY-294002","pmids":["18272487"],"confidence":"High","gaps":["How Gq activation leads to Akt downregulation (rather than activation as in hippocampus) remains unexplained","Cell-type determinants of pro-survival versus pro-apoptotic outcome unknown"]},{"year":2010,"claim":"Discovery of CYM2503 as a positive allosteric modulator of GALR2 demonstrated that GALR2 Gq signaling can be potentiated without competing at the orthosteric galanin binding site, opening a new pharmacological modality with in vivo anticonvulsant efficacy.","evidence":"IP1 accumulation assay and radioligand binding in HEK293/GalR2 cells; rat Li-pilocarpine and mouse electroshock seizure models","pmids":["20660766"],"confidence":"High","gaps":["Allosteric binding site on GALR2 not mapped","Selectivity over GalR1/GalR3 in vivo not fully characterized"]},{"year":2014,"claim":"Two parallel advances: (1) GalR1-GalR2 heteroreceptor complexes were shown to allosterically shape galanin fragment selectivity between Gi and Gq outputs; (2) GALR2 was found to drive tumor angiogenesis through p38/RAP1B-mediated TTP inactivation and VEGF/IL-6 mRNA stabilization.","evidence":"BRET2 and PLA in HEK293T cells with CRE/NFAT reporters for heteromers; ELISA, in vitro angiogenesis, genetic knockdown of RAP1B/TTP, mouse xenograft and CAM models for angiogenesis","pmids":["25152404","24568968"],"confidence":"High","gaps":["Stoichiometry and structural architecture of GalR1-GalR2 heteromer unknown","Whether TTP-dependent mechanism operates in cancers beyond HNSCC not tested"]},{"year":2022,"claim":"Loss-of-function studies in cardiomyocytes and cardiac tissue established GALR2 as a cardioprotective receptor whose suppression promotes hypertrophy, fibrosis, and mitochondrial oxidative stress, extending GALR2 biology beyond the nervous system.","evidence":"GalR2 genetic suppression in mice and siRNA in H9C2 cardiomyoblasts with cardiac histology and mitochondrial ROS measurement; validated with selective agonist/antagonist in ischemia-reperfusion model","pmids":["35431947","37249014"],"confidence":"Medium","gaps":["Downstream signaling pathway (Gq versus Gi versus biased) mediating cardioprotection not dissected","Single-lab findings await independent replication"]},{"year":2025,"claim":"Conditional knockout studies revealed that GALR2 can signal through beta-arrestin2 independently of canonical Gq coupling to protect the gut epithelial barrier and suppress colitis, establishing biased agonism as a physiologically relevant GALR2 signaling mode.","evidence":"Galr2 knockout, epithelial cell-specific Arrb2 and Gnaq conditional knockout mice in DSS-induced colitis model with colon histology and inflammatory markers","pmids":["41390752"],"confidence":"High","gaps":["Whether beta-arrestin2 bias is ligand-dependent (cGAL53-specific) or generalizable to all GALR2 agonists unknown","Structural basis for biased signaling at GALR2 not determined"]},{"year":null,"claim":"Major unresolved questions include the structural basis for GALR2's preferential Gq coupling, cholesterol binding, and allosteric modulation; the cell-type determinants that switch GALR2 output between pro-survival (Akt/ERK) and pro-apoptotic (Akt/Bad) fates; and whether beta-arrestin2-biased signaling operates in neuronal and cardiac contexts.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of GALR2 available","Cell-type switching mechanism between neuroprotection and apoptosis undefined","Beta-arrestin2 bias characterized only in gut epithelium"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,2,3]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[13,14]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,4,11,14]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[7,8,10,11]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[9,12]}],"complexes":["GalR1-GalR2 heteroreceptor complex"],"partners":["GALR1","GNAQ","GNAI","ARRB2","RAP1B","ZFP36"],"other_free_text":[]},"mechanistic_narrative":"GALR2 is a galanin receptor that functions as a Gq/G11-coupled GPCR activating phospholipase C, inositol phosphate production, and intracellular calcium mobilization, with secondary coupling to Gi/Go-mediated cAMP inhibition and a recently established beta-arrestin2-biased signaling arm [PMID:9578554, PMID:9685625, PMID:41390752]. Downstream of Gq, GALR2 engages PKC-dependent MAPK activation, Akt/ERK-mediated neuroprotection in hippocampal neurons, and PKC-dependent neurite outgrowth from sensory neurons, while also triggering caspase-3-dependent apoptosis through Akt/Bad downregulation in neuroblastoma and PC12 cells [PMID:12533601, PMID:17263796, PMID:14592962, PMID:18272487]. Ligand binding requires membrane cholesterol, which cooperatively modulates both receptor affinity and Gq-dependent signaling independently of G protein coupling [PMID:10508403]. GALR2 forms heteroreceptor complexes with GalR1 that allosterically reshape ligand selectivity between Gi and Gq pathways, and in peripheral tissues drives tumor angiogenesis via RAP1B/p38/TTP-dependent stabilization of VEGF and IL-6 mRNAs and protects the gut epithelium through beta-arrestin2-biased anti-inflammatory signaling [PMID:25152404, PMID:24568968, PMID:41390752]."},"prefetch_data":{"uniprot":{"accession":"O43603","full_name":"Galanin receptor type 2","aliases":[],"length_aa":387,"mass_kda":41.7,"function":"Receptor for the hormone galanin and GALP. Receptor for the hormone spexin-1 (PubMed:24517231). The activity of this receptor is mediated by G proteins that activate the phospholipase C/protein kinase C pathway (via G(q)) and that inhibit adenylyl cyclase (via G(i))","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/O43603/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GALR2","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GALR2","total_profiled":1310},"omim":[{"mim_id":"619246","title":"SPEXIN HORMONE; SPX","url":"https://www.omim.org/entry/619246"},{"mim_id":"616461","title":"EPILEPSY, FAMILIAL TEMPORAL LOBE, 8; ETL8","url":"https://www.omim.org/entry/616461"},{"mim_id":"611178","title":"GALANIN-LIKE PEPTIDE; GALP","url":"https://www.omim.org/entry/611178"},{"mim_id":"610935","title":"ZINC-ACTIVATED ION CHANNEL; ZACN","url":"https://www.omim.org/entry/610935"},{"mim_id":"603823","title":"FREE FATTY ACID RECEPTOR 2; FFAR2","url":"https://www.omim.org/entry/603823"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":7.3}],"url":"https://www.proteinatlas.org/search/GALR2"},"hgnc":{"alias_symbol":["GALNR2"],"prev_symbol":[]},"alphafold":{"accession":"O43603","domains":[{"cath_id":"1.20.1070.10","chopping":"24-215_229-312","consensus_level":"high","plddt":92.0454,"start":24,"end":312}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O43603","model_url":"https://alphafold.ebi.ac.uk/files/AF-O43603-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O43603-F1-predicted_aligned_error_v6.png","plddt_mean":77.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GALR2","jax_strain_url":"https://www.jax.org/strain/search?query=GALR2"},"sequence":{"accession":"O43603","fasta_url":"https://rest.uniprot.org/uniprotkb/O43603.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O43603/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O43603"}},"corpus_meta":[{"pmid":"10379831","id":"PMC_10379831","title":"Expression of the novel galanin receptor subtype GALR2 in the adult rat CNS: distinct distribution from GALR1.","date":"1999","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10379831","citation_count":282,"is_preprint":false},{"pmid":"9578554","id":"PMC_9578554","title":"Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes.","date":"1998","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9578554","citation_count":212,"is_preprint":false},{"pmid":"11481429","id":"PMC_11481429","title":"Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: selective actions via GalR1 and GalR2 receptors.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11481429","citation_count":181,"is_preprint":false},{"pmid":"9832121","id":"PMC_9832121","title":"Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3.","date":"1998","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9832121","citation_count":148,"is_preprint":false},{"pmid":"12533601","id":"PMC_12533601","title":"The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons.","date":"2003","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12533601","citation_count":117,"is_preprint":false},{"pmid":"17263796","id":"PMC_17263796","title":"Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage.","date":"2007","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17263796","citation_count":94,"is_preprint":false},{"pmid":"17257664","id":"PMC_17257664","title":"Galanin receptor subtype 2 (GalR2) null mutant mice display an anxiogenic-like phenotype specific to the elevated plus-maze.","date":"2007","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/17257664","citation_count":92,"is_preprint":false},{"pmid":"10508403","id":"PMC_10508403","title":"Membrane cholesterol modulates galanin-GalR2 interaction.","date":"1999","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10508403","citation_count":85,"is_preprint":false},{"pmid":"14592962","id":"PMC_14592962","title":"Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells.","date":"2003","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/14592962","citation_count":67,"is_preprint":false},{"pmid":"15899880","id":"PMC_15899880","title":"Phenotypic analysis of mice deficient in the type 2 galanin receptor (GALR2).","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15899880","citation_count":67,"is_preprint":false},{"pmid":"9685625","id":"PMC_9685625","title":"Molecular characterization, pharmacological properties and chromosomal localization of the human GALR2 galanin receptor.","date":"1998","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9685625","citation_count":66,"is_preprint":false},{"pmid":"18554714","id":"PMC_18554714","title":"Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests.","date":"2008","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/18554714","citation_count":64,"is_preprint":false},{"pmid":"15514977","id":"PMC_15514977","title":"Characterization of GalR1, GalR2, and GalR3 immunoreactivity in catecholaminergic nuclei of the mouse brain.","date":"2004","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15514977","citation_count":60,"is_preprint":false},{"pmid":"10450874","id":"PMC_10450874","title":"Expression of the galanin receptor subtype Gal-R2 mRNA in the rat hypothalamus.","date":"1999","source":"Journal of chemical neuroanatomy","url":"https://pubmed.ncbi.nlm.nih.gov/10450874","citation_count":59,"is_preprint":false},{"pmid":"19159918","id":"PMC_19159918","title":"Analyzing the validity of GalR1 and GalR2 antibodies using knockout mice.","date":"2009","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19159918","citation_count":57,"is_preprint":false},{"pmid":"9480833","id":"PMC_9480833","title":"Cloning and expression of the human galanin receptor GalR2.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9480833","citation_count":53,"is_preprint":false},{"pmid":"9928165","id":"PMC_9928165","title":"Distribution and characterization of the cell types expressing GALR2 mRNA in brain and pituitary gland.","date":"1998","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9928165","citation_count":45,"is_preprint":false},{"pmid":"9742938","id":"PMC_9742938","title":"The GalR2 galanin receptor mediates galanin-induced jejunal contraction, but not feeding behavior, in the rat: differentiation of central and peripheral effects of receptor subtype activation.","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9742938","citation_count":44,"is_preprint":false},{"pmid":"9681481","id":"PMC_9681481","title":"Inducible galanin and GalR2 receptor system in motor neuron injury and regeneration.","date":"1998","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9681481","citation_count":43,"is_preprint":false},{"pmid":"9880084","id":"PMC_9880084","title":"Cloning and characterization of the human galanin GALR2 receptor.","date":"1998","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/9880084","citation_count":41,"is_preprint":false},{"pmid":"19467704","id":"PMC_19467704","title":"A novel GalR2-specific peptide agonist.","date":"2009","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/19467704","citation_count":39,"is_preprint":false},{"pmid":"18272487","id":"PMC_18272487","title":"Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2).","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18272487","citation_count":38,"is_preprint":false},{"pmid":"18081561","id":"PMC_18081561","title":"The effects of galanin-like peptide on energy balance, body temperature and brain activity in the mouse and rat are independent of the GALR2/3 receptor.","date":"2008","source":"Journal of neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/18081561","citation_count":37,"is_preprint":false},{"pmid":"25152404","id":"PMC_25152404","title":"Preferential activation by galanin 1-15 fragment of the GalR1 protomer of a GalR1-GalR2 heteroreceptor complex.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25152404","citation_count":36,"is_preprint":false},{"pmid":"10803589","id":"PMC_10803589","title":"Expression of GalR1 and GalR2 galanin receptor messenger ribonucleic acid in proopiomelanocortin neurons of the rat arcuate nucleus: effect of testosterone.","date":"2000","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10803589","citation_count":36,"is_preprint":false},{"pmid":"20121116","id":"PMC_20121116","title":"Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery.","date":"2010","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20121116","citation_count":35,"is_preprint":false},{"pmid":"9832122","id":"PMC_9832122","title":"The mouse GalR2 galanin receptor: genomic organization, cDNA cloning, and functional characterization.","date":"1998","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9832122","citation_count":33,"is_preprint":false},{"pmid":"21281311","id":"PMC_21281311","title":"GalR2/3 mediates proliferative and trophic effects of galanin on postnatal hippocampal precursors.","date":"2011","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21281311","citation_count":32,"is_preprint":false},{"pmid":"34923235","id":"PMC_34923235","title":"Baicalin protects against insulin resistance and metabolic dysfunction through activation of GALR2/GLUT4 signaling.","date":"2021","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34923235","citation_count":31,"is_preprint":false},{"pmid":"15934937","id":"PMC_15934937","title":"GalR1, but not GalR2 or GalR3, levels are regulated by galanin signaling in the locus coeruleus through a cyclic AMP-dependent mechanism.","date":"2005","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15934937","citation_count":29,"is_preprint":false},{"pmid":"17910903","id":"PMC_17910903","title":"Selective stimulation of GalR1 and GalR2 in rat substantia gelatinosa reveals a cellular basis for the anti- and pro-nociceptive actions of galanin.","date":"2007","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/17910903","citation_count":28,"is_preprint":false},{"pmid":"24568968","id":"PMC_24568968","title":"The G protein-coupled receptor GALR2 promotes angiogenesis in head and neck cancer.","date":"2014","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24568968","citation_count":28,"is_preprint":false},{"pmid":"20660766","id":"PMC_20660766","title":"GalR2-positive allosteric modulator exhibits anticonvulsant effects in animal models.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20660766","citation_count":27,"is_preprint":false},{"pmid":"32841709","id":"PMC_32841709","title":"Palmitate differentially regulates Spexin, and its receptors Galr2 and Galr3, in GnRH neurons through mechanisms involving PKC, MAPKs, and TLR4.","date":"2020","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32841709","citation_count":24,"is_preprint":false},{"pmid":"17157570","id":"PMC_17157570","title":"Galanin treatment offsets the inhibition of bone formation and downregulates the increase in mouse calvarial expression of TNFalpha and GalR2 mRNA induced by chronic daily injections of an injurious vehicle.","date":"2006","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/17157570","citation_count":21,"is_preprint":false},{"pmid":"25347995","id":"PMC_25347995","title":"Analgesic properties of a peripherally acting and GalR2 receptor-preferring galanin analog in inflammatory, neuropathic, and acute pain models.","date":"2014","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25347995","citation_count":19,"is_preprint":false},{"pmid":"9928164","id":"PMC_9928164","title":"Cloning and evaluation of the role of rat GALR-2, a novel subtype of galanin receptor, in the control of pain perception.","date":"1998","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9928164","citation_count":18,"is_preprint":false},{"pmid":"36599082","id":"PMC_36599082","title":"GALR2 and Y1R agonists intranasal infusion enhanced adult ventral hippocampal neurogenesis and antidepressant-like effects involving BDNF actions.","date":"2023","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/36599082","citation_count":17,"is_preprint":false},{"pmid":"28098336","id":"PMC_28098336","title":"Preclinical evaluation of intravenous NAX 810-2, a novel GalR2-preferring analog, for anticonvulsant efficacy and pharmacokinetics.","date":"2017","source":"Epilepsia","url":"https://pubmed.ncbi.nlm.nih.gov/28098336","citation_count":17,"is_preprint":false},{"pmid":"17143559","id":"PMC_17143559","title":"Galanin enhances corticosterone secretion from dispersed rat adrenocortical cells through the activation of GAL-R1 and GAL-R2 receptors coupled to the adenylate cyclase-dependent signaling cascade.","date":"2007","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17143559","citation_count":14,"is_preprint":false},{"pmid":"18595677","id":"PMC_18595677","title":"Immunohistochemical localization of galanin receptors (GAL-R1, GAL-R2, and GAL-R3) on myenteric neurons from the sheep and dog stomach.","date":"2008","source":"Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft","url":"https://pubmed.ncbi.nlm.nih.gov/18595677","citation_count":13,"is_preprint":false},{"pmid":"36551197","id":"PMC_36551197","title":"Galanin Receptors (GALR1, GALR2, and GALR3) Immunoexpression in Enteric Plexuses of Colorectal Cancer Patients: Correlation with the Clinico-Pathological Parameters.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36551197","citation_count":12,"is_preprint":false},{"pmid":"22982974","id":"PMC_22982974","title":"Identification and characterization of the chicken galanin receptor GalR2 and a novel GalR2-like receptor (GalR2-L).","date":"2012","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22982974","citation_count":12,"is_preprint":false},{"pmid":"35431947","id":"PMC_35431947","title":"Galanin Regulates Myocardial Mitochondrial ROS Homeostasis and Hypertrophic Remodeling Through GalR2.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35431947","citation_count":11,"is_preprint":false},{"pmid":"36848750","id":"PMC_36848750","title":"Decreased medial prefrontal cortex activity related to impaired novel object preference task performance following GALR2 and Y1R agonists intranasal infusion.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36848750","citation_count":11,"is_preprint":false},{"pmid":"35346778","id":"PMC_35346778","title":"Effects of intracerebroventricular injection of spexin and its interaction with NPY, GalR2 and GalR3 receptors on the central food intake regulation and nutritional behavior in broiler chickens.","date":"2022","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/35346778","citation_count":10,"is_preprint":false},{"pmid":"34203944","id":"PMC_34203944","title":"Regulatory Influence of Galanin and GALR1/GALR2 Receptors on Inflamed Uterus Contractility in Pigs.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34203944","citation_count":10,"is_preprint":false},{"pmid":"27175780","id":"PMC_27175780","title":"The Influence of Gastric Antral Ulcerations on the Expression of Galanin and GalR1, GalR2, GalR3 Receptors in the Pylorus with Regard to Gastric Intrinsic Innervation of the Pyloric Sphincter.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27175780","citation_count":10,"is_preprint":false},{"pmid":"36039037","id":"PMC_36039037","title":"The GAL/GALR2 axis promotes the perineural invasion of salivary adenoid cystic carcinoma via epithelial-to-mesenchymal transition.","date":"2022","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36039037","citation_count":9,"is_preprint":false},{"pmid":"28382595","id":"PMC_28382595","title":"Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2.","date":"2017","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/28382595","citation_count":9,"is_preprint":false},{"pmid":"27021209","id":"PMC_27021209","title":"Homology modeling, docking, and molecular dynamics simulation of the receptor GALR2 and its interactions with galanin and a positive allosteric modulator.","date":"2016","source":"Journal of molecular modeling","url":"https://pubmed.ncbi.nlm.nih.gov/27021209","citation_count":8,"is_preprint":false},{"pmid":"31249471","id":"PMC_31249471","title":"Galanin Protects Rat Cortical Astrocyte from Oxidative Stress: Involvement of GalR2 and pERK1/2 Signal Pathway.","date":"2019","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/31249471","citation_count":6,"is_preprint":false},{"pmid":"35527373","id":"PMC_35527373","title":"Chimeric Agonist of Galanin Receptor GALR2 Reduces Heart Damage in Rats with Streptozotocin-Induced Diabetes.","date":"2022","source":"Biochemistry. Biokhimiia","url":"https://pubmed.ncbi.nlm.nih.gov/35527373","citation_count":6,"is_preprint":false},{"pmid":"23142608","id":"PMC_23142608","title":"Galanin, through GalR1 but not GalR2 receptors, decreases motivation at times of high appetitive behavior.","date":"2012","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/23142608","citation_count":6,"is_preprint":false},{"pmid":"36055012","id":"PMC_36055012","title":"Levels of spexin and its receptors GALR2 and GALR3 in the hypothalamus and ovary of letrozole-induced polycystic ovary syndrome in rats.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/36055012","citation_count":6,"is_preprint":false},{"pmid":"38425430","id":"PMC_38425430","title":"Neuropeptide Y receptor 1 and galanin receptor 2 (NPY1R-GALR2) interactions in the dentate gyrus and their relevance for neurogenesis and cognition.","date":"2024","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/38425430","citation_count":6,"is_preprint":false},{"pmid":"38622072","id":"PMC_38622072","title":"Enhanced neuronal survival and BDNF elevation via long-term co-activation of galanin 2 (GALR2) and neuropeptide Y1 receptors (NPY1R): potential therapeutic targets for major depressive disorder.","date":"2024","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/38622072","citation_count":5,"is_preprint":false},{"pmid":"38549164","id":"PMC_38549164","title":"Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions.","date":"2024","source":"Behavioral and brain functions : BBF","url":"https://pubmed.ncbi.nlm.nih.gov/38549164","citation_count":5,"is_preprint":false},{"pmid":"38572811","id":"PMC_38572811","title":"Long-term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co-administration of neuropeptide Y 1 receptor (NPY1R) and galanin receptor 2 (GALR2) agonists in the ventral hippocampus.","date":"2024","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/38572811","citation_count":5,"is_preprint":false},{"pmid":"36580831","id":"PMC_36580831","title":"Investigating the potential of GalR2 as a drug target for neuropathic pain.","date":"2022","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/36580831","citation_count":3,"is_preprint":false},{"pmid":"10491278","id":"PMC_10491278","title":"Characterization of hypothalamic neurons expressing a neuropeptide receptor, GALR2, using combined in situ hybridization-immunohistochemistry.","date":"1999","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/10491278","citation_count":3,"is_preprint":false},{"pmid":"37249014","id":"PMC_37249014","title":"Exogenous GalR2-specific peptide agonist as a tool for treating myocardial ischemia/reperfusion injury.","date":"2023","source":"Fundamental & clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37249014","citation_count":3,"is_preprint":false},{"pmid":"38632282","id":"PMC_38632282","title":"Glyphosate-induced changes in the expression of galanin and GALR1, GALR2 and GALR3 receptors in the porcine small intestine wall.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38632282","citation_count":3,"is_preprint":false},{"pmid":"41390752","id":"PMC_41390752","title":"A novel long-galanin peptide from non-mammalian vertebrates mitigates the inflammatory response in IBD models via the biased GALR2/β-arrestin2 pathway.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41390752","citation_count":0,"is_preprint":false},{"pmid":"41570651","id":"PMC_41570651","title":"The role of galanin/GALR2 signaling in the link between type 2 diabetes and Alzheimer's disease.","date":"2026","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/41570651","citation_count":0,"is_preprint":false},{"pmid":"41307298","id":"PMC_41307298","title":"Intracerebroventricular knockdown of NPY1R disrupts NPY1R-GALR2/TrkB heteroreceptor complexes without affecting neuroplasticity or depressive-like behaviour.","date":"2025","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/41307298","citation_count":0,"is_preprint":false},{"pmid":"35717583","id":"PMC_35717583","title":"[The anti-ischemic and antioxidant activity of the pharmacological agonist of galanin receptor GalR2 and carnosine in in vitro and in vivo model systems].","date":"2022","source":"Biomeditsinskaia khimiia","url":"https://pubmed.ncbi.nlm.nih.gov/35717583","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":36543,"output_tokens":6127,"usd":0.100767},"stage2":{"model":"claude-opus-4-6","input_tokens":9686,"output_tokens":3415,"usd":0.200708},"total_usd":0.301475,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"GalR2 couples to Gq/G11 to stimulate phospholipase C and inositol phosphate production (7-fold increase), and also couples modestly to Gi (30% inhibition of forskolin-stimulated cAMP) and Go-mediated MAPK activation in CHO cells; GalR2-mediated MAPK activation is PKC-dependent and not sensitive to beta-ARKct (Gbetagamma inhibitor), distinguishing it mechanistically from GalR1.\",\n      \"method\": \"Stable CHO cell expression, cAMP assay, inositol phosphate accumulation, MAPK activity assay, pertussis toxin treatment, PKC inhibitor, beta-ARKct expression\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal signaling assays in stably transfected cells with pharmacological dissection of G protein coupling\",\n      \"pmids\": [\"9578554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Human GALR2 couples to Galphaq/11 to stimulate phospholipase C and increase intracellular calcium, and also to Galphai/o to inhibit adenylate cyclase; high-affinity galanin binding (Kd ~0.3 nM) requires intact N-terminal but not C-terminal galanin fragments.\",\n      \"method\": \"Stable HEK-293 expression, [125I]galanin radioligand binding, cAMP assay, calcium/aequorin luminescence, Xenopus melanophore assay\",\n      \"journal\": \"Brain research. Molecular brain research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal functional assays confirmed in human receptor expressed in two heterologous systems\",\n      \"pmids\": [\"9685625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Human GALR2 couples to phospholipase C/calcium mobilization, distinguishing it from GALR1 and GALR3 which signal predominantly through inhibition of adenylate cyclase; galanin binds with Kd ~0.3 nM.\",\n      \"method\": \"Radioligand binding ([125I]galanin), aequorin luminescence calcium assay, Xenopus melanophore assay in HEK-293 cells\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — orthogonal pharmacological characterization of human receptor replicated across multiple cell systems\",\n      \"pmids\": [\"9832121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Mouse GalR2 signals through phosphoinositide metabolism (Gq-coupled) in a pertussis toxin-insensitive manner, confirming Gq (not Gi/Go) as the primary coupling partner; high-affinity galanin binding (Kd = 0.47 nM) requires N-terminal but not C-terminal galanin sequences.\",\n      \"method\": \"COS-7 cell transfection, [125I]galanin radioligand binding, phosphoinositide metabolism assay, pertussis toxin treatment\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro reconstitution with pharmacological dissection, replicated across species\",\n      \"pmids\": [\"9832122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Membrane cholesterol is required for galanin binding to GalR2; depletion by methyl-beta-cyclodextrin or lipoprotein-deficient serum markedly reduces binding, which is restored by cholesterol repletion. GalR2 binds multiple cholesterol molecules cooperatively (Hill n ≥ 3). Cholesterol also modulates downstream Gq/inositol phosphate signaling, independently of G protein interaction.\",\n      \"method\": \"Cholesterol depletion/repletion in CHO/GalR2 cells, radioligand binding, Hill analysis, filipin clustering, cholesterol oxidase treatment, inositol phosphate assay, GTPgammaS preincubation\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal perturbations with rigorous controls establishing cholesterol as a mechanistic regulator of GalR2 ligand binding and signaling\",\n      \"pmids\": [\"10508403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"GalR2 is the receptor subtype mediating galanin-induced jejunal contraction; pharmacological profile of GalR-selective ligands in jejunal contraction matched only GalR2, and only GalR2 mRNA was detected in the tissue.\",\n      \"method\": \"GalR-selective ligand pharmacology in rat jejunal contraction assay, Northern blot/RT-PCR for receptor mRNA\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological matching with receptor expression, single lab\",\n      \"pmids\": [\"9742938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"GalR2 mRNA is markedly upregulated (~3.7-fold at day 7) in facial motor neurons after unilateral facial nerve crush, while GalR1 mRNA is absent in facial nuclei; this inducible GalR2 upregulation suggests an autoreceptor role in nerve injury response.\",\n      \"method\": \"In situ hybridization histochemistry quantification after facial nerve crush in rats\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct quantitative measurement of receptor mRNA with injury model, single lab\",\n      \"pmids\": [\"9681481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"GalR2 receptor activation mediates pronociceptive (allodynic) effects of low-dose galanin in the spinal cord; intrathecal infusion of the GalR2-specific agonist AR-M1896 induces mechanical and cold allodynia in normal rats, whereas antiallodynic effects of high-dose galanin in neuropathic pain are mediated by GalR1.\",\n      \"method\": \"Intrathecal infusion of GalR2-selective agonist AR-M1896 and GalR1/2 agonist AR-M961 in rat Bennett neuropathic pain model, mechanical and cold allodynia testing\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — selective agonist pharmacology with defined behavioral readout, replicated across receptor subtypes in vivo\",\n      \"pmids\": [\"11481429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"GalR2 activation mediates galanin-induced neurite outgrowth from adult dorsal root ganglion sensory neurons via a PKC-dependent signaling pathway; GalR2-specific agonist has equipotent effects to galanin on neurite extension, PKC inhibition reduces outgrowth to galanin-knockout levels, and GalR1 knockout/antagonism has no effect.\",\n      \"method\": \"GalR1 knockout animals, GalR1-specific antagonist, GalR2-specific agonist, PKC inhibitor, DRG neurite outgrowth assay, galanin knockout cultures\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout plus selective pharmacological tools with quantitative cellular readout, multiple converging lines of evidence\",\n      \"pmids\": [\"12533601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"GalR2 activation in SH-SY5Y neuroblastoma cells induces apoptosis via caspase-3 activation, PARP cleavage, and DNA laddering; this effect is far more potent (100-fold lower EC50) and pronounced than GalR1 activation in the same cell type.\",\n      \"method\": \"Tetracycline-inducible GalR1/GalR2 expression in SH-SY5Y cells, cell viability, caspase-3 activation, PARP cleavage, DNA laddering, microphysiometry\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — inducible receptor expression system with multiple apoptosis markers, direct receptor-subtype comparison\",\n      \"pmids\": [\"14592962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"GalR2 mediates neuroprotection in hippocampal neurons by activating Akt and ERK phosphorylation; galanin-induced Akt phosphorylation is abolished in GalR2 loss-of-function mutant animals. Inhibitors of ERK or Akt confirm that GalR2-dependent activation of these kinases contributes to protection against glutamate-induced cell death.\",\n      \"method\": \"GalR2 loss-of-function mutant mice, hippocampal cultures, galanin/glutamate treatment, Western blot for pAkt and pERK, specific kinase inhibitors\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function plus pharmacological inhibitors with quantitative signaling readouts\",\n      \"pmids\": [\"17263796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"GalR2 is expressed presynaptically in substantia gelatinosa neurons, where its activation by selective agonist AR-M1896 consistently decreases membrane excitability and increases the interevent interval of spontaneous EPSCs; GalR1 cocktail does not affect EPSCs, demonstrating distinct pre- versus postsynaptic localization.\",\n      \"method\": \"Whole-cell patch-clamp recording from rat substantia gelatinosa neurons, GalR2-selective agonist AR-M1896, GalR2 antagonist M871, current-voltage analysis, EPSC recording\",\n      \"journal\": \"Pain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — electrophysiology with selective agonist/antagonist tools establishing pre- and postsynaptic actions\",\n      \"pmids\": [\"17910903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"GalR2 activation in PC12 cells stably expressing GFP-tagged GalR2 induces caspase-dependent apoptosis via Gq/11-type signaling, associated with downregulation of pAkt and pBad; PI3K inhibition increases pBad and decreases caspase activation, confirming PI3K/Akt pathway involvement downstream of GalR2.\",\n      \"method\": \"Stable GFP-GalR2 transfection in PC12 cells, Western blot for pAkt/pBad, caspase activation assay, PI3K inhibitor LY-294002, FACS cell cycle analysis, real-time PCR\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal assays with pharmacological dissection of downstream pathway\",\n      \"pmids\": [\"18272487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CYM2503, a positive allosteric modulator of GalR2, potentiates galanin-stimulated IP1 accumulation in HEK293/GalR2 cells without displacing [125I]galanin from the orthosteric binding site, demonstrating allosteric modulation of GalR2 Gq signaling; this compound shows anticonvulsant efficacy in rodent seizure models.\",\n      \"method\": \"IP1 accumulation assay in HEK293/GalR2 cells, [125I]galanin radioligand binding competition, rat Li-pilocarpine seizure model, mouse electroshock model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic binding and signaling assays confirming allosteric mechanism, validated in vivo\",\n      \"pmids\": [\"20660766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GalR1 and GalR2 form heteroreceptor complexes detectable by proximity ligation assay (PLA) and BRET2 in HEK293T cells and in the raphe-hippocampal system; within these complexes, galanin(1-15) preferentially activates the GalR1 protomer (inhibiting CREB/cAMP via Gi) while galanin(1-29) shows higher efficacy at the GalR2 protomer (activating Gq/NFAT signaling), revealing allosteric receptor-receptor interactions.\",\n      \"method\": \"Proximity ligation assay, BRET2 assay in HEK293T cells, CRE luciferase reporter, NFAT luciferase reporter, GalR2 antagonist M871, galanin antagonist M35\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal assays (BRET2, PLA, functional reporters) establishing heteroreceptor complex formation and biased signaling\",\n      \"pmids\": [\"25152404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GALR2 promotes tumor angiogenesis in head and neck squamous cell carcinoma via p38-MAPK-mediated activation of RAP1B, which phosphorylates/inactivates tristetraprolin (TTP), stabilizing VEGF and IL-6 mRNA transcripts and enhancing their secretion; p38 inhibition reactivates TTP and decreases cytokine secretion.\",\n      \"method\": \"ELISA for cytokines, in vitro angiogenesis assay, p38 chemical inhibitor, genetic knockdown of RAP1B and TTP, mouse xenograft, chick chorioallantoic membrane, orthotopic floor-of-mouth model\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — chemical and genetic knockdown strategies with in vitro and in vivo validation, mechanistic pathway dissection\",\n      \"pmids\": [\"24568968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GALR2 activation by baicalin upregulates GLUT4 expression and glucose uptake through p38MAPK and AKT pathways and the PGC-1alpha-GLUT4 axis in skeletal muscle; GALR2 antagonist M871 and GALR2 siRNA knockdown abolish these effects, demonstrating that GALR2 is the required mediator.\",\n      \"method\": \"Obese mouse model with GALR2 antagonist M871, GALR2 knockdown L6 myotubes, Western blot for PGC-1alpha/GLUT4/p-p38/p-AKT/p-AS160, glucose consumption assay\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown plus pharmacological antagonism with defined signaling readouts, single lab\",\n      \"pmids\": [\"34923235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GalR2 is the dominant galanin receptor subtype in mouse cardiomyocytes and hearts; genetic suppression of GalR2 promotes cardiac hypertrophy, fibrosis, and mitochondrial oxidative stress in vivo, while GalR2 siRNA in vitro abolishes galanin's protective effects against cell hypertrophy and mitochondrial ROS production.\",\n      \"method\": \"GalR2 genetic suppression in mice, siRNA knockdown in H9C2 cardiomyoblasts, cardiac histology, mitochondrial ROS measurement\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro loss-of-function with defined cardiac phenotypes, single lab\",\n      \"pmids\": [\"35431947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Nerve-derived galanin activates GALR2 in salivary adenoid cystic carcinoma cells, inducing epithelial-to-mesenchymal transition (EMT) and promoting perineural invasion; GALR2 antagonist M871 blocks these effects both in vitro and in vivo.\",\n      \"method\": \"Transcriptome sequencing, Western blot for EMT markers, Transwell invasion assay, in vitro and in vivo perineural invasion models, GALR2 antagonist M871\",\n      \"journal\": \"Cancer medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition with in vitro and in vivo models, mechanistic pathway identification\",\n      \"pmids\": [\"36039037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GalR2 is the principal receptor subtype transducing cardioprotective effects of galanin in myocardial ischemia/reperfusion injury; the GalR2-selective agonist peptide G1 (1 mg/kg i.v.) reduced infarct size by 35% and CK-MB activity by 43%, and these effects were abolished by the selective GalR2 antagonist M871.\",\n      \"method\": \"LAD coronary artery occlusion/reperfusion in rats, GalR2-selective agonist and antagonist (M871), infarct size measurement, plasma CK-MB activity\",\n      \"journal\": \"Fundamental & clinical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective pharmacological tools with defined cardiac readouts in vivo, antagonist rescue confirms receptor specificity\",\n      \"pmids\": [\"37249014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GALR2 mediates the anti-inflammatory effects of a naturally occurring long galanin isoform (cGAL53) via beta-arrestin2-biased signaling rather than canonical Gq; these effects were abolished in Galr2-deficient mice and in epithelial cell-specific Arrb2 knockout mice, demonstrating that GALR2/beta-arrestin2 pathway protects the gut barrier and reduces colitis-associated inflammation.\",\n      \"method\": \"Galr2 knockout mice, epithelial cell-specific Arrb2 and Gnaq conditional knockouts, DSS-induced colitis model, colon histology, inflammatory markers\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple conditional knockout models orthogonally dissecting canonical vs. biased GALR2 signaling with in vivo disease model validation\",\n      \"pmids\": [\"41390752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"GAL-R2, expressed in rat adrenocortical cells, couples to the adenylate cyclase/PKA signaling cascade to stimulate corticosterone secretion; immunoblockade of GAL-R2 (and GAL-R1) reduced galanin binding and abolished cAMP and corticosterone responses, while PLC inhibitor and PKC inhibitor had no effect.\",\n      \"method\": \"Dispersed rat adrenocortical cells, immunoblockade of receptor subtypes, [3H]galanin binding, cAMP and inositol phosphate assays, adenylate cyclase inhibitor SQ-22536, PKA inhibitor H-89, PKC inhibitor\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection with multiple inhibitors in primary cells, context-specific cAMP coupling distinct from CHO cell data\",\n      \"pmids\": [\"17143559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GalR2/3 activation by Gal2-11 promotes proliferation and trophic survival of postnatal hippocampal subgranular zone precursors and neuroblasts; no effect was observed via GalR1, demonstrating receptor-subtype specificity for hippocampal neurogenesis.\",\n      \"method\": \"Postnatal hippocampal precursor culture, GalR2/3 agonist Gal2-11, proliferation and survival assays\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — subtype-selective agonist with defined cellular readout, single lab\",\n      \"pmids\": [\"21281311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GalR2 mediates galanin's protective effects against oxidative stress in rat cortical astrocytes; GalR2 agonist AR-M1896 mimics galanin protection against H2O2 toxicity and suppresses H2O2-induced upregulation of pERK1/2, with GalR2 showing higher expression than GalR1 or GalR3 in these cells.\",\n      \"method\": \"Primary rat cortical astrocyte culture, H2O2 oxidative stress, GalR2-selective agonist AR-M1896, Western blot for pERK1/2, cell viability assay\",\n      \"journal\": \"Mediators of inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective agonist with signaling pathway readout in primary cells, single lab\",\n      \"pmids\": [\"31249471\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GALR2 is a Gq/G11-coupled (and modestly Gi/Go-coupled) GPCR that, upon galanin binding, activates phospholipase C/PKC signaling to drive inositol phosphate production, calcium mobilization, and PKC-dependent MAPK activation; downstream of these pathways GALR2 promotes neurite outgrowth, hippocampal neuroprotection (via Akt and ERK), sensory neuron sensitization (pronociception at low doses), neuroblastoma/PC12 cell apoptosis (via caspase-3 and Akt/Bad), tumor angiogenesis (via RAP1B/p38/TTP/VEGF-IL-6), and gut epithelial protection (via beta-arrestin2-biased signaling); membrane cholesterol is required for ligand binding and downstream signaling, and GALR2 can form heteroreceptor complexes with GalR1 (and NPY1R) that allosterically reshape its pharmacology.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"GALR2 is a galanin receptor that functions as a Gq/G11-coupled GPCR activating phospholipase C, inositol phosphate production, and intracellular calcium mobilization, with secondary coupling to Gi/Go-mediated cAMP inhibition and a recently established beta-arrestin2-biased signaling arm [PMID:9578554, PMID:9685625, PMID:41390752]. Downstream of Gq, GALR2 engages PKC-dependent MAPK activation, Akt/ERK-mediated neuroprotection in hippocampal neurons, and PKC-dependent neurite outgrowth from sensory neurons, while also triggering caspase-3-dependent apoptosis through Akt/Bad downregulation in neuroblastoma and PC12 cells [PMID:12533601, PMID:17263796, PMID:14592962, PMID:18272487]. Ligand binding requires membrane cholesterol, which cooperatively modulates both receptor affinity and Gq-dependent signaling independently of G protein coupling [PMID:10508403]. GALR2 forms heteroreceptor complexes with GalR1 that allosterically reshape ligand selectivity between Gi and Gq pathways, and in peripheral tissues drives tumor angiogenesis via RAP1B/p38/TTP-dependent stabilization of VEGF and IL-6 mRNAs and protects the gut epithelium through beta-arrestin2-biased anti-inflammatory signaling [PMID:25152404, PMID:24568968, PMID:41390752].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Establishing the primary signaling identity of GALR2: multiple groups independently demonstrated that GALR2 couples predominantly to Gq/G11 to activate PLC and inositol phosphate/calcium signaling, with modest Gi/Go-mediated cAMP inhibition and PKC-dependent MAPK activation, distinguishing it mechanistically from GalR1 and GalR3.\",\n      \"evidence\": \"Heterologous expression in CHO, HEK-293, COS-7, and Xenopus melanophore systems with cAMP, inositol phosphate, calcium, and MAPK assays plus pertussis toxin and PKC inhibitor dissection\",\n      \"pmids\": [\"9578554\", \"9685625\", \"9832121\", \"9832122\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous G-protein stoichiometry may differ from overexpression systems\", \"Structural basis for preferential Gq over Gi coupling unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identifying GALR2 as the functional galanin receptor subtype in smooth muscle contraction resolved which receptor mediates galanin's gut motility effects, linking GALR2 Gq signaling to a defined physiological output.\",\n      \"evidence\": \"Pharmacological profiling with GalR-selective ligands in rat jejunal contraction assay combined with Northern blot/RT-PCR\",\n      \"pmids\": [\"9742938\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genetic confirmation with GALR2 knockout in gut tissue not performed\", \"Downstream contractile signaling pathway not dissected\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrating that membrane cholesterol is an obligate modulator of GALR2 ligand binding and downstream Gq signaling revealed a lipid-dependent regulatory layer operating independently of G-protein coupling.\",\n      \"evidence\": \"Cholesterol depletion/repletion in CHO/GalR2 cells with radioligand binding, Hill analysis, and inositol phosphate assays\",\n      \"pmids\": [\"10508403\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct cholesterol binding site on GALR2 not identified\", \"No structural data for cholesterol-receptor interaction\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing GALR2 as a pronociceptive receptor in the spinal cord — where low-dose galanin induces allodynia via GALR2 while high-dose antiallodynia is GalR1-mediated — resolved a long-standing paradox of galanin's bidirectional effects on pain.\",\n      \"evidence\": \"Intrathecal infusion of GalR2-selective agonist AR-M1896 in rat neuropathic pain model with mechanical and cold allodynia testing\",\n      \"pmids\": [\"11481429\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream intracellular pathway linking GALR2 activation to allodynia not identified\", \"GALR2 knockout confirmation not performed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Two independent studies established GALR2 as an effector of both neurite outgrowth (via PKC) in sensory neurons and caspase-3-dependent apoptosis in neuroblastoma cells, revealing divergent cell-type-dependent outcomes of the same Gq/PKC pathway.\",\n      \"evidence\": \"GalR1 knockout mice plus selective agonist/antagonist pharmacology in DRG neurite outgrowth assay; inducible GalR2 expression in SH-SY5Y with caspase-3, PARP cleavage, and DNA laddering assays\",\n      \"pmids\": [\"12533601\", \"14592962\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Branching point determining growth versus death outcome not identified\", \"Role of Gi coupling in apoptosis not excluded\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Genetic loss-of-function in mice demonstrated that GALR2 is required for galanin-induced Akt and ERK phosphorylation in hippocampal neurons and for protection against glutamate excitotoxicity, establishing GALR2 as a neuroprotective receptor.\",\n      \"evidence\": \"GalR2 loss-of-function mutant mice, hippocampal cultures, Western blot for pAkt/pERK, kinase inhibitors\",\n      \"pmids\": [\"17263796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nature of the GalR2 loss-of-function allele limits generalizability\", \"Relative contribution of Akt versus ERK arm not fully resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Electrophysiological recordings established that GALR2 acts presynaptically in spinal substantia gelatinosa neurons to decrease excitability and modulate excitatory synaptic transmission, providing a synaptic-level mechanism for galanin's sensory modulatory effects.\",\n      \"evidence\": \"Whole-cell patch-clamp with GalR2-selective agonist AR-M1896 and antagonist M871 in rat substantia gelatinosa neurons\",\n      \"pmids\": [\"17910903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ion channel target downstream of presynaptic GALR2 not identified\", \"Post-synaptic GalR2 contributions not fully dissected\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mechanistic dissection in PC12 cells revealed that GALR2-induced apoptosis proceeds via Gq-coupled downregulation of pAkt and pBad, placing Bad dephosphorylation as the specific pro-apoptotic switch downstream of GALR2.\",\n      \"evidence\": \"Stable GFP-GalR2 PC12 cells, Western blot for pAkt/pBad, caspase assay, PI3K inhibitor LY-294002\",\n      \"pmids\": [\"18272487\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Gq activation leads to Akt downregulation (rather than activation as in hippocampus) remains unexplained\", \"Cell-type determinants of pro-survival versus pro-apoptotic outcome unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery of CYM2503 as a positive allosteric modulator of GALR2 demonstrated that GALR2 Gq signaling can be potentiated without competing at the orthosteric galanin binding site, opening a new pharmacological modality with in vivo anticonvulsant efficacy.\",\n      \"evidence\": \"IP1 accumulation assay and radioligand binding in HEK293/GalR2 cells; rat Li-pilocarpine and mouse electroshock seizure models\",\n      \"pmids\": [\"20660766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Allosteric binding site on GALR2 not mapped\", \"Selectivity over GalR1/GalR3 in vivo not fully characterized\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Two parallel advances: (1) GalR1-GalR2 heteroreceptor complexes were shown to allosterically shape galanin fragment selectivity between Gi and Gq outputs; (2) GALR2 was found to drive tumor angiogenesis through p38/RAP1B-mediated TTP inactivation and VEGF/IL-6 mRNA stabilization.\",\n      \"evidence\": \"BRET2 and PLA in HEK293T cells with CRE/NFAT reporters for heteromers; ELISA, in vitro angiogenesis, genetic knockdown of RAP1B/TTP, mouse xenograft and CAM models for angiogenesis\",\n      \"pmids\": [\"25152404\", \"24568968\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural architecture of GalR1-GalR2 heteromer unknown\", \"Whether TTP-dependent mechanism operates in cancers beyond HNSCC not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Loss-of-function studies in cardiomyocytes and cardiac tissue established GALR2 as a cardioprotective receptor whose suppression promotes hypertrophy, fibrosis, and mitochondrial oxidative stress, extending GALR2 biology beyond the nervous system.\",\n      \"evidence\": \"GalR2 genetic suppression in mice and siRNA in H9C2 cardiomyoblasts with cardiac histology and mitochondrial ROS measurement; validated with selective agonist/antagonist in ischemia-reperfusion model\",\n      \"pmids\": [\"35431947\", \"37249014\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream signaling pathway (Gq versus Gi versus biased) mediating cardioprotection not dissected\", \"Single-lab findings await independent replication\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Conditional knockout studies revealed that GALR2 can signal through beta-arrestin2 independently of canonical Gq coupling to protect the gut epithelial barrier and suppress colitis, establishing biased agonism as a physiologically relevant GALR2 signaling mode.\",\n      \"evidence\": \"Galr2 knockout, epithelial cell-specific Arrb2 and Gnaq conditional knockout mice in DSS-induced colitis model with colon histology and inflammatory markers\",\n      \"pmids\": [\"41390752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether beta-arrestin2 bias is ligand-dependent (cGAL53-specific) or generalizable to all GALR2 agonists unknown\", \"Structural basis for biased signaling at GALR2 not determined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major unresolved questions include the structural basis for GALR2's preferential Gq coupling, cholesterol binding, and allosteric modulation; the cell-type determinants that switch GALR2 output between pro-survival (Akt/ERK) and pro-apoptotic (Akt/Bad) fates; and whether beta-arrestin2-biased signaling operates in neuronal and cardiac contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of GALR2 available\", \"Cell-type switching mechanism between neuroprotection and apoptosis undefined\", \"Beta-arrestin2 bias characterized only in gut epithelium\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 2, 3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [13, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 4, 11, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 1, 2, 3, 10, 14]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [7, 8, 10, 11]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [9, 12]}\n    ],\n    \"complexes\": [\n      \"GalR1-GalR2 heteroreceptor complex\"\n    ],\n    \"partners\": [\n      \"GALR1\",\n      \"GNAQ\",\n      \"GNAI\",\n      \"ARRB2\",\n      \"RAP1B\",\n      \"ZFP36\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}